Background: The patient's immune response is one of the major factors infl uencing HBV eradication or chronifi cation, and it is thought to be responsible for the treatment success. Aim: Our study aimed to investigate whether cellular defense mechanisms are associated with the course of HBV infection (spontaneous recovery [SR] or chronifi cation [CHB]) and with the therapeutic approach. Patients and methods: A total of 139 patients (118 with CHB, 21 SR) and 29 healthy individuals (HI) were immunophenotyped by fl owcytometry. Fifty-six patients were treatment-naïve, 20 were treated with interferons and 42 with nucleoside/nucleotide analogues. Results: Defi ciency of T lymphocytes, helper-inducer (CD3+CD4+), suppressorcytotoxic (CD8+CD3+) and cytotoxic (CD8+CD11b-, CD8+CD28+) subsets, activated T cells (CD3+HLA-DR+, CD8+CD38+) and increased CD57+CD8-cells, elevated percentages of B lymphocytes and NKT cells were observed in CHB patients compared with HI. In SR patients, elevated CD8+CD11b+, NKT and activated T cells were found in comparison with controls. The higher values of T cells and their subsets in SR patients than in CHB patients refl ect a recovery of cellular immunity in resolved HBV infection individuals. In both groups of treated patients, reduced T lymphocytes, CD3+CD4+ and CD8+CD38+ subsets were found in comparison with HI. Higher proportions of cytotoxic subsets were observed in treated patients compared with treatment-naïve CHB patients, more pronounced in the group with interferon therapy. Conclusion: Our data demonstrate that cellular immune profi les may be of prognostic value in predicting the clinical course of HBV infection, and the determination of the therapeutic response.
Infection with hepatitis virus B (HBV) represents a global healthcare and social problem. An estimated 240 million people are chronically infected with hepatitis B (defi ned as hepatitis B surface antigen positive for at least 6 months). 1 The incidence of HBV infection in the general Bulgarian population is as high as 5%, which places Bulgaria among the regions in Europe with high prevalence of the infection. However, in comparison with the global prevalence rates according to recent reports it is in the lower-intermediate endemicity regions (2) (3) (4) .99%). 2 The immunopathogenesis of chronic HBV infection is not fully understood. After HBV contamination both innate and adaptive immune responses are triggered to overcome the virus and ultimately terminate the infection. It is generally acknowledged that the host B-cell response (anti-HBV antibodies) contributes to the virus clearance and prevents viral spread while the cellular immune response is the most important factor in killing infected cells and is thought to be responsible for both viral clearance and disease pathogenesis during hepatitis B virus infection. 3 In chronic infection, the severity of liver involvement is thought to depend on many factors including the host immune response, the virus itself (e.g. viral genome and mutants) and the environmental infl uence. Any changes or dysfunction of the cellular immunity seem to be crucial for anti-HBV defense and thus for defi ning which individual will develop a chronic infection and which one will spontaneously clear the virus. The anti-viral treatment is also very important for disease outcome but its impact on the cellular immune response is not extensively studied.
AIM
To investigate whether the cellular immune response may be associated with the course of HBV infection (spontaneous recovery or chronifi cation) and with the type of therapy chosen: interferons or nucleoside/ nucleotide analogues.
PATIENTS AND METHODS

MATERIALS
A total of 139 patients were enrolled in the study. These included 118 patients with chronic hepatitis B (84 men, 34 women, mean age 44±27 yrs; range 18-73 yrs) and 21 spontaneously recovered (SR) patients from acute infection (11 men, 10 women, mean age 44±13.5 yrs; range 31-58 yrs). The recruitment of patients for the study was carried out in the Department of Gastroenterology at the Clinic of Propaedeutics of Internal Diseases, Alexandrovska University Hospital and Clinic of Infectious Diseases, Military Medical Academy, Sofi a after clinical and laboratory evaluation according to predefi ned inclusion and exclusion criteria. The diagnosis of chronic hepatitis B (CHB) infection was based on the recommendations of the American Association for the Study of Liver Diseases. Co-morbidities, including HCV and HDV hepatitis, as well as other infections, tumors, autoimmune and infl ammatory conditions were excluded. Fifty-six patients were newly diagnosed and treatment-naïve at the time of the study. Twenty patients were treated with interferons -IFN (Peg interferon α-2a) and 42 with nucleoside/nucleotide analogues (NA). The survey included 29 randomly selected unrelated healthy subjects from the general Bulgarian population, ageand sex-matched with the study patients, without a family history of inherited diseases, with normal liver function and negative serological markers for viral hepatitis. Clinical and laboratory signs of infection potentially infl uencing the immune cell populations were not detected in the controls. Healthy subjects were included to assess whether there were immune profi les in patients with hepatitis B associated with impaired defense mechanisms resulting in aggravation of the disease. All enrolled patients and healthy subjects signed informed consent. 
METHODS
Investigation of immune cells
RESULTS
As a fi rst step we examined the cellular immune response in HBV-infected patients and control group. Comparing the group of CHB patients with healthy individuals we found the following statistically signifi cant differences ( Table 1) : defi ciency of total CD3+ T lymphocytes due to a reduction of their helper-inducer, suppressor-cytotoxic and cytotoxic (CD8+CD11b-; CD8+CD28+) subsets; increased CD57+CD8-cells with NK cell activity and decreased activated total T cells (CD3+HLA-DR+) and CD8+ lymphocytes expressing CD38 activation marker (CD8+CD38+); elevated percentages of B lymphocytes and NKT [CD3+(CD16+56)+] cells.
In patients spontaneously recovered from HBV infection we found the following statistically signifi cant differences in comparison with the healthy subjects: elevated CD8+CD11b+ cells (including T lymphocytes with suppressor function), NKT lymphocytes, CD57+CD8-NK cells, activated total T lymphocytes (CD3+HLA-DR+) and CD8+CD38+ cell subset.
The comparative analysis between both patients' groups ( Table 1) showed statistically signifi cantly higher values of total T cells and their helper-inducer (CD3+CD4+), suppressor-cytotoxic (CD8+CD3+) and effector (cytotoxic) and/or memory subpopulations (CD8+CD28+) in SR versus CHB patients which is due to normalization of these immunological parameters in the individuals who have resolved their HBV infection (Fig. 1) . We also observed elevated activated T cells (CD3+HLA-DR+, CD8+CD38+) and NKT cells in patients recovered from the infection.
In order to assess whether treatment may have impact on the cellular immune response of chronically infected HBV individuals ( Table 2) we made a comparison between both patients' groups under therapy (treated with IFN and treated with NA), and between treated and untreated patients and cytotoxic (CD3+CD8+) T lymphocytes (Fig. 2) mainly due to higher cytotoxic CD8+CD11b-subset in treated patients (Fig. 3) . The increase of effector (cytotoxic) cells was more pronounced in the group of interferon treated patients. Analysis of the data showed that as a result of ongoing treatment the percentage of these T-cell subpopulations approached the reference values with their absolute number remaining low.
DISCUSSION
Detection of HBsAg is the fi rst serological marker of hepatitis B infection and its persistence in patients for more than six months is an indication of a chronic infection. However, the majority of patients cleared the virus and were categorized as spontaneously recovered. The antiviral immune response, particularly the T cell arm, is an important factor for the outcome of infection; it has been shown that chronic HBV infection correlates with the occurrence of dysfunctional immune responses. 11 Although many studies have studied the role of changes in the immune responses during HBV infection, some questions remain unanswered such as the relationship between the changes in the immune cells subpopulations and disease outcome, the relationships of the latter with HBV replication activity as well as the infl uence of antiviral therapy. Taking in consideration that the intensity and type of host antiviral immune response are vital for the disease course and outcome we have investigated the changes in immune cells populations and subpopulations in HBV infected patients. With this approach we aimed to help the assessment of the success of viral elimination or response to therapeutic strategies. Summarizing our results we can conclude that in patients with chronic hepatitis B the alterations in immune responses concern both acquired and innate immunity. The observed deficiency of T lymphocytes and their helper-inducer (CD3+CD4+) subset was consistent with the results of other researchers. [12] [13] [14] However, the data on changes in suppressor-cytotoxic (CD3+CD8+) T cells in HBV infection are contradictory. Like other researchers 14, 15 , we have found lower number of suppressor-cytotoxic T-cell subpopulations mainly related with a defi ciency of effector (cytotoxic) subsets in treatment naïve patients with CHB. Taking into consideration the importance of cytotoxic T cells response for suppression of HBV replication and viral elimination, Mukherjee et al. 16 assumed that the selective reduction of cytotoxic (CD8+), but not of helper (CD4+) T cells may be indicative of persistent HBV infection. Our fi nding also supports the suggested impairment of the effector arm of the adaptive immunity responsible for the effective viral elimination. Like Sun et al. 17 we found elevated relative B-cell numbers in all patients' groups compared to healthy subjects, which could be associated with an active specifi c humoral immune response against HBV. Signifi cant reduction in the number of NK cells was observed in chronic HBV patients compared with healthy controls. 18, 19 The absence of changes in total NK cells [CD3-(CD16+56)+] in our study could be due to the fact that these cells are involved in the early, nonspecifi c immune response against the virus. 20 found an increased proportion, but not absolute number of activated CD8+CD38+ T cells in patients with chronic hepatitis B in comparison with HBV carriers and healthy controls, and the percentage decreases to normal values as a result of NA therapy. However, the decrease of these cells observed in our CHB patients did not support the above observation. The same authors reported a defi ciency in absolute values of CD8+CD28+ cells with effector and/or memory functions which was consistent with our data. It is noteworthy that the data of Li et al. 21 demonstrating high level of CD8 + CD28 − subpopulations and low CD28 + /CD28 − ratio in the CD8 + T cell population in patients with hepatitis B in comparison to healthy controls. Since CD8 + CD28 + T cells participate in virus clearance a decrease in CD28 expression may lead to T cell dysfunction, lower CTL activity and diffi culty to clear HBV infection. 21 Discrepancies between our results and those from other investigators can be explained by the fact that the chronic HBV infection has a dynamic course and depending on the disease progression different immune disturbances could be observed.
On the other hand, after spontaneous recovery from HBV infection the immune parameters usually return to normal, indicating a recovery of the patient's immune reactivity. 22 It is interesting to note the elevated activated T cells (CD3+HLA-DR+, CD8+CD38+) and NKT cells found in our SR individuals. In connection with this it should be mentioned that Yu et al. 23 showed a signifi cantly higher proportion of CD8+CD38+ cells at week 24 of Peg-INFα-2a treatment in responders as compared to non-responders to therapy. The authors explained this fi nding with the fact that an increased expression of CD38 on CD8+ lymphocytes is suggestive of intensive cellular immunity in CHB patients that may promote the HBsAg clearance. 23 Our data also suggest that antiviral therapy infl uences the cellular immune response, resulting in the recovery of its effector integrity which is more pronounced in patients treated with interferons. The antiviral therapy can overcome the hypo-responsiveness of CD8+ T cells (including effector cytotoxic T-cell subsets) in individuals with CHB suggesting that these T-cell subpopulations exist, but are suppressed in infected patients. 24 Consistent to this are the results of Li et al. 21 for increased proportions of CD8 + CD28 + antigen-primed cytotoxic T cells and CD8 + CD28 + / CD8 + CD28 − T cells ratio, and decreased levels of CD8 + CD28 − suppressor T cells in chronic HBV patients given effective therapy with Peg-IFN-α.
In conclusion, our results showed that the surface markers used to defi ne immune cell populations and subpopulations by multicolor fl owcytometry are suffi ciently informative for evaluation of both the innate and acquired immune response of patients with HBV infection. Therefore, our study of cell populations in patients with different course of HBV infection could be benefi cial for the differentiation of immune profi les characteristic for chronic hepatitis B or recovery from infection. Moreover, the immune profi les investigated in treated CHB patients may be used as biomarkers for estimating the effect of antiviral therapy. Future studies including expansion of the set of immunological markers by testing additional cell subpopulations (e.g. Treg) and markers such as CD27, TCRγδ etc. will allow more complete and detailed evaluation of the cellular immune response in HBV and other viral infections.
